These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21584812)

  • 1. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
    Castella B; Vitale C; Coscia M; Massaia M
    Cell Mol Life Sci; 2011 Jul; 68(14):2419-32. PubMed ID: 21584812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
    Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
    Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for "signal 2": costimulation requirements of γδ T cells.
    Ribot JC; debarros A; Silva-Santos B
    Cell Mol Life Sci; 2011 Jul; 68(14):2345-55. PubMed ID: 21541698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
    Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
    Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Vgamma9Vdelta2 T cells: from signals to functions.
    Nedellec S; Bonneville M; Scotet E
    Semin Immunol; 2010 Aug; 22(4):199-206. PubMed ID: 20447835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The way of interaction between Vγ9Vδ2 T cells and tumor cells.
    Zhang T; Wang J; Zhao A; Xia L; Jin H; Xia S; Shi T
    Cytokine; 2023 Feb; 162():156108. PubMed ID: 36527892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.
    Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G
    J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
    Lafont V; Liautard J; Liautard JP; Favero J
    J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
    Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
    Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.
    Lesport E; Baudhuin J; Sousa S; LeMaoult J; Zamborlini A; Rouas-Freiss N; Carosella ED; Favier B
    Cell Mol Life Sci; 2011 Oct; 68(20):3385-99. PubMed ID: 21337044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
    Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
    Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How tumors might withstand γδ T-cell attack.
    Capietto AH; Martinet L; Fournié JJ
    Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling between immunological synapse formation and functional outcome in human gamma delta T lymphocytes.
    Favier B; Espinosa E; Tabiasco J; Dos Santos C; Bonneville M; Valitutti S; Fournié JJ
    J Immunol; 2003 Nov; 171(10):5027-33. PubMed ID: 14607899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells.
    Chauvin C; Joalland N; Perroteau J; Jarry U; Lafrance L; Willem C; Retière C; Oliver L; Gratas C; Gautreau-Rolland L; Saulquin X; Vallette FM; Vié H; Scotet E; Pecqueur C
    Clin Cancer Res; 2019 Dec; 25(23):7218-7228. PubMed ID: 31506386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells.
    Joalland N; Scotet E
    Front Immunol; 2020; 11():992. PubMed ID: 32528477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
    Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
    Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.